

Davide Lombardi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9927761/publications.pdf>

Version: 2024-02-01

16
papers

296
citations

1307594

7
h-index

888059

17
g-index

17
all docs

17
docs citations

17
times ranked

623
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 1601-1610. | 1.6 | 100 |
| 2 | Familial breast cancer: characteristics and outcome of BRCA 1&2 positive and negative cases. <i>BMC Cancer</i> , 2005, 5, 70. | 2.6 | 73 |
| 3 | A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies. <i>Breast Cancer Research</i> , 2011, 13, R117. | 5.0 | 30 |
| 4 | New oral drugs in older patients: a review of idarubicin in elderly patients. <i>Critical Reviews in Oncology/Hematology</i> , 2004, 49, 153-163. | 4.4 | 29 |
| 5 | Ultrasound Microvascular Blood Flow Evaluation: A New Tool for the Management of Thyroid Nodule?. <i>International Journal of Endocrinology</i> , 2019, 2019, 1-6. | 1.5 | 18 |
| 6 | Continuous Infusion Fluorouracil in the Management of Advanced Breast Cancer: A Phase II Study. <i>Tumori</i> , 2000, 86, 42-45. | 1.1 | 10 |
| 7 | Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients. <i>BMC Cancer</i> , 2014, 14, 954. | 2.6 | 9 |
| 8 | Lapatinib-Based Therapy in Heavily Pretreated HER2-Positive Metastatic Breast Cancer: A Single Institution Experience. <i>Tumori</i> , 2012, 98, 33-38. | 1.1 | 4 |
| 9 | Ultrasound of benign thyroid nodules: A 120 months follow-up study. <i>Clinical Endocrinology</i> , 2021, 94, 866-871. | 2.4 | 4 |
| 10 | Incidence of Palmar-Plantar Erythrodysesthesia in Pretreated and Unpretreated Patients Receiving Pegylated Liposomal Doxorubicin. <i>Tumori</i> , 2009, 95, 687-690. | 1.1 | 3 |
| 11 | Selecting for BRCA1 testing using a combination of homogeneous selection criteria and immunohistochemical characteristics of breast cancers. <i>BMC Cancer</i> , 2009, 9, 360. | 2.6 | 3 |
| 12 | Epirubicin and Docetaxel as Neoadjuvant Treatment of Locally Advanced Breast Cancer: A Phase II Study. <i>Tumori</i> , 2010, 96, 229-233. | 1.1 | 3 |
| 13 | Idarubicin. <i>Tumori</i> , 2002, 88, S73-S74. | 1.1 | 2 |
| 14 | Epirubicin and docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: findings from two successive phase II studies. <i>Radiology and Oncology</i> , 2013, 47, 57-62. | 1.7 | 2 |
| 15 | Epirubicin and docetaxel as neoadjuvant treatment of locally advanced breast cancer: a phase II study. <i>Tumori</i> , 2010, 96, 229-33. | 1.1 | 2 |
| 16 | KIR-HLA Functional Repertoire Influences Trastuzumab Efficiency in Patients With HER2-Positive Breast Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 791958. | 4.8 | 2 |